This design template pertains to the Phase 2 Single-Arm Clinical Trial to Evaluate the Safety and Efficacy of the BCMA-Targeting Bispecific Antibody AAA in Combination with Immunomodulatory Drug (IMiD) BBB in Subjects with High-Risk Relapsed/Refractory Multiple Myeloma.